

Mr. GIORDANO. We have our permissive section in the Bureau, which is geared to the regulatory controls and close coordination with the medical profession and pharmaceutical profession. Actually though, I would say that at all levels of the headquarters staff we maintain continual communication with the medical professional, with the pharmaceutical industry, the pharmaceutical profession, HEW, and the National Institute of Mental Health. We have an informed advisory commission that is a combination of the American Medical Association Committee on Drug Dependence and the National Research Council Committee on Drug Dependence that advises me on the medical aspects relating to narcotics and the proper medical or legitimate use of drugs. We have been in very close association with the National Institute of Mental Health, particularly in recent years, in regard to their studies of the effects of marihuana. We provide the material—they do all of the research. We need to continue this type of an operation, even though we are enforcement people. We have to know the views of the medical people on this and the problems that they see.

Chairman BLATNIK. Mr. Secretary, we will have to continue your interrogation tomorrow. We had hoped it would not be necessary to continue over. Will it be possible for you to be here tomorrow morning?

Mr. HENDRICK. Certainly it would. If I could get away by 11:30 I would appreciate it.

Chairman BLATNIK. Yes. We will put you on first thing tomorrow morning.

Mr. EDWARDS. I would say about 10:30 he would be done.

Chairman BLATNIK. We would appreciate that very much.

Mr. Giordano, I have started off the interrogation with you. It would be very helpful, Mr. Finlator, we are imposing again on you, but could you be here again tomorrow?

Mr. FINLATOR. I would be delighted.

Chairman BLATNIK. We certainly express our appreciation. You have been most patient and cooperative.

We have received for insertion in the record a statement of Hon. L. H. Fountain, a statement of Hon. Seymour Halpern, and a statement of Hon. Silvio O. Conte.

(The above-mentioned statements follow:)

STATEMENT OF HON. L. H. FOUNTAIN, A REPRESENTATIVE IN CONGRESS
FROM THE STATE OF NORTH CAROLINA

Mr. Chairman and members of the subcommittee; I appreciate the opportunity to appear before you today to present my views on the President's Reorganization Plan No. 1 of 1968. The Intergovernmental Relations Subcommittee, a sister subcommittee to this one, and of which I have the honor to be Chairman, has been studying the drug safety activities of the Food and Drug Administration quite intensively for the past several years.

One of the areas which the subcommittee has studied in some detail is FDA's implementation of its responsibilities under the Drug Abuse Control Act of 1965. More recently, the subcommittee looked into problems relating to the control of marihuana and at the relationship between FDA's Bureau of Drug Abuse Control and the Treasury Department's Bureau of Narcotics. From these studies it was quite apparent that there are problems of cooperation and coordination resulting not only from the organizational division of responsibility but also from inconsistencies in the laws under which these two agencies operate.